Bipolar Clinical Trials in Miami, Florida
14 recruitingMiami, Florida
Showing 1–14 of 14 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Bipolar DisorderMania
Bristol-Myers Squibb424 enrolled103 locationsNCT07140913
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled74 locationsNCT06951711
Recruiting
Phase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
Bristol-Myers Squibb450 enrolled170 locationsNCT06929273
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bipolar-I Disorder With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled63 locationsNCT06951698
Recruiting
Phase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled19 locationsNCT07105111
Recruiting
Phase 2
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
Bipolar I or II Disorder
AbbVie200 enrolled49 locationsNCT07220460
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Bipolar DisorderBipolar I DisorderBipolar II Disorder+1 more
Xenon Pharmaceuticals Inc.400 enrolled27 locationsNCT07172516
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
DepressionBipolar I Disorder
AbbVie380 enrolled80 locationsNCT04777357
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
Bipolar Disorder Depression
Autobahn Therapeutics, Inc.35 enrolled15 locationsNCT06869187
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Bipolar Depression
Intra-Cellular Therapies, Inc.384 enrolled59 locationsNCT06372964
Recruiting
Phase 3
Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
Bipolar Disorder, Manic
Intra-Cellular Therapies, Inc.350 enrolled42 locationsNCT06462586
Recruiting
Phase 3
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Bipolar Disorder, Manic
Intra-Cellular Therapies, Inc.350 enrolled35 locationsNCT06462612